Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Gaudium IVF and Women Health share price today

GAUDIUMIVFHealthcare servicesConsolidatedPrices to 20 Nov 2026Results to Sep 2026

10Y not available: listed Feb 2026
Price, 200-day average and NIFTY 500Since Feb 2026Since Feb 2026

The price is 6.6% below its 200-day average and 21 points ahead of the NIFTY 500 since listing in Feb 2026

20 Nov 2026₹99.57Since listing in Feb 2026: Gaudium IVF and Women Health +24.1%, NIFTY 500 +3.2%
₹75₹150May 26Aug 26Nov 26

Price growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

EPS and P/ESince Feb 2026Since Feb 2026

EPS ₹3.27, down 10% in a year; P/E 30.4

20 Nov 2026₹3.27 EPS
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹4

EPS growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

Revenue and marginsSince Feb 2026Insufficient history, from Mar 2022

Revenue up on a year for 4 quarters in a row; operating margin 36.0%

Sep 2026 quarter₹37 crore+17.9% on ₹32 crore a year earlier · NPM 25.2%
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹40

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+22.9%3Y+33.2%/yr to Mar
Rev 5Y, Rev growth10YToo short
OPM average3Y38.6% to Mar5Y39.5% to Mar
NPM average3Y23.8% to Mar5Y25.0% to Mar

Return on capitalInsufficient history, from Mar 2023Insufficient history, from Mar 2023

ROCE was 25.2% for the four quarters to Sep 2026, down from 76.0% in the year to Mar 2023

Four quarters to Sep 202625.2% ROCEInsufficient history: data from Mar 2023
20%60%Sep 23Sep 24Sep 25Sep 26

ROCE average

1Y3Y5Y10Y1Y25.2%3Y41.1% to Mar5YToo short10YToo short

Profit and cashSince Feb 2026Insufficient history, from Mar 2022

Cash from operations was 55% of profit over five years, 29% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹7 crore operating cashProfit ₹24 crore · Free cash ₹0 crore
FY22
FY23
FY24
FY25
FY26
0₹25

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+3.9%3Y+19.7%/yr to Mar5YToo short10YToo short

ReinvestmentSince Feb 2026Insufficient history, from Mar 2022

Capex was ₹7 crore in the year to Mar 2026, 2.3 times depreciation

FY26₹7 crore capexWork in progress ₹12 crore
FY22
FY23
FY24
FY25
FY26
0₹20

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−22.2% to Mar3Y−22.4%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Sep 2024Insufficient history, from Sep 2024

Debt ÷ equity 0.14 at 30 Sep 2026; profit covered interest 10.0x over the last four quarters

Sep 2026 balance sheet0.14 debt ÷ equityNet debt ₹3 crore
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
030x

Safety

Now3Y ago
Debt ÷ equity0.143Y agon/a
Int. cover10.0x3Y agon/a

Operating healthSince Feb 2026Since Feb 2026

Working capital rose from 61 to 91 days since FY22

Year to Mar 202691 days working capital
0100Mar 23Mar 24Mar 25Mar 26
Working cap.911Y+473Y+1435YToo short
Debtor1871Y+173Y+1795YToo short
Inventory381Y−1373Y−735YToo short

OwnershipInsufficient history, from Mar 2026Insufficient history, from Mar 2026

FIIs own 1.19%; no figure a year earlier. Promoters hold 71.29%

Share of the company held, %, by quarter end

Sep 2026 quarter1.19% FIIsNo figure a year earlier
0%60%Jun 26Sep 26

FIIs 1Y, FIIs 3Y, Promoters 1Y, Promoters

3Y3YToo short

Gaudium IVF and Women Health Ltd · GAUDIUMIVF · Hospitals/Medical Services · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 16 November 2026

Gaudium IVF and Women Health share price today: ₹99.57 at the close on 20 November 2026. Gaudium IVF and Women Health (GAUDIUMIVF) is worth ₹726 crore and trades at a P/E of 30.4. Latest change: foreign funds (FIIs) cut their stake for 3 quarters in a row.

₹99.57Price
30.4×P/E lower than 89% of the last 8 months
₹37.4 CrRevenue (Sep 2026) +17.9% on a year ago
₹9.4 CrProfit (Sep 2026) +0.3% on a year ago
36.0%Operating margin −7.4 points on a year ago
25.2%ROCE four quarters to Sep 2026
15.2%ROIC against a 12.0% cost of capital: +3.2 points
36%Profit that came in as cash last 3 years

Gaudium IVF and Women Health Ltd's results are improving, while its P/E is near the low end of its own history over 8 months, higher than only 11% of past readings.

The main question: profits are rising, but only 36% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.

The price is in an uptrend that has just slipped below its 200-day average, and the P/E is lower than 89% of its own last 8 months. Over the last four quarters, results have been improving, with profit +0.3% on a year earlier, and 36% of the last 3 years' profit came in as cash. What will decide it: whether the cash starts to follow the profit.

What is the Gaudium IVF and Women Health share price today?

Gaudium IVF and Women Health Ltd's share price was ₹99.57 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 6.6% below its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Gaudium IVF and Women Health Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 10 April 2026, it has traded between ₹92 and ₹158, and at that close it sat 11% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running.

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 14 of 26 weeks

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
10 Apr 2026no NIFTY 500 reading
17 Apr 2026no NIFTY 500 reading
24 Apr 2026no NIFTY 500 reading
30 Apr 2026no NIFTY 500 reading
8 May 2026no NIFTY 500 reading
15 May 2026no NIFTY 500 reading
22 May 2026no NIFTY 500 reading
29 May 2026no NIFTY 500 reading
4 Jun 2026no NIFTY 500 reading
5 Jun 2026no NIFTY 500 reading
10 Jun 2026no NIFTY 500 reading
12 Jun 2026no NIFTY 500 reading
17 Jun 2026no NIFTY 500 reading
19 Jun 2026+10.7%
24 Jun 2026+13.3%
25 Jun 2026−15.1%
1 Jul 2026−7.8%
3 Jul 2026−1.1%
10 Jul 2026+11.6%
17 Jul 2026+21.9%
24 Jul 2026+28.7%
31 Jul 2026+22.9%
7 Aug 2026+18.2%
14 Aug 2026+14.5%
21 Aug 2026+7.8%
28 Aug 2026+14.8%
4 Sep 2026+6.6%
11 Sep 2026+7.3%
18 Sep 2026+8.2%
25 Sep 2026+3.0%
1 Oct 2026−0.2%
9 Oct 2026−8.5%
16 Oct 2026−24.9%
23 Oct 2026−32.9%
30 Oct 2026−16.3%
6 Nov 2026−19.4%
8 Nov 2026−12.8%
13 Nov 2026−5.6%
20 Nov 2026−19.1%
Each bar is one week, from 2026 to now (26 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 7 months the share price moved +5% while the NIFTY 500 moved +6%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Gaudium IVF and Women Health this quarter?

4 points on a year earlier and revenue up on a year earlier for 4 quarters in a row.

  1. Foreign funds (FIIs) cut their stake for 3 quarters in a row

    From 9.2% to 1.2% of the company by the September 2026 quarter.

  2. Operating margin down 7.4 points on a year earlier

    36% in the September 2026 quarter, from 43.4%.

  3. Revenue up on a year earlier for 4 quarters in a row

    In the September 2026 quarter revenue was ₹37 crore, +17.9% on a year earlier.

What are Gaudium IVF and Women Health's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Gaudium IVF and Women Health reported revenue of ₹37.4 crore, up 17.9% from ₹31.7 crore a year earlier, and a profit of ₹9.41 crore, up 0.3% from ₹9.38 crore.

Gaudium IVF and Women Health results: July to September 2026 against a year earlier

Gaudium IVF and Women Health results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹37.4 crore₹31.7 crore+17.9%
Profit₹9.41 crore₹9.38 crore+0.3%
Earnings per share₹1.29₹1.53−15.7%
Operating margin36.0%43.4%−7.4 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Gaudium IVF and Women Health's management discussed these results on a call held on 16 November 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Gaudium IVF and Women Health share price history?

Gaudium IVF and Women Health closed at ₹99.57 on 20 November 2026. Its highest weekly close since April 2026 was ₹151.90 on 24 July 2026.

Gaudium IVF and Women Health share price: then and now

Gaudium IVF and Women Health share price: then and now
WhenCloseChange to 20 Nov 2026
1 week ago · 13 Nov 2026₹106.14−6.2%
1 month ago · 19 Oct 2026₹97.58+2.0%
6 months ago · 22 May 2026₹115.07−13.5%
Earliest weekly close in our records · 10 Apr 2026₹95.13+4.7%
Highest weekly close since April 2026 · 24 Jul 2026₹151.90−34.5%
Lowest weekly close since April 2026 · 23 Oct 2026₹92.11+8.1%

Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

39 weekly closes from 10 April 2026 to 20 November 2026.

What is the latest news on Gaudium IVF and Women Health?

20 Nov 2026: Gaudium IVF and Women Health closed at ₹99.57, down 6.2% on the week and up 2.0% on the month. 16 Nov 2026: Gaudium IVF and Women Health held its results call for July to September 2026. Management guided: FY27 revenue ₹130 crore reaffirmed with hub rollout on schedule and stronger H2 expected.

Earlier

  • Results for July to September 2026: Revenue up 17.9% and profit up 0.3% on a year earlier.

What dividend does Gaudium IVF and Women Health pay?

Gaudium IVF and Women Health has paid no dividend on the exchange since its first close in our records (10 April 2026), the start of the period we checked.

No. Gaudium IVF and Women Health Ltd paid out 0% of its profit as dividends in each of its last 5 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 20 November 2026.

What did Gaudium IVF and Women Health management say on the latest results call?

On the call for July to September 2026, held on 16 November 2026, Gaudium IVF and Women Health's management guided: FY27 revenue ₹130 crore reaffirmed with hub rollout on schedule and stronger H2 expected.

“Historically, our new hubs have broken even within about 3-6 months of launch, and I am happy to share that South Extension is also almost breaking even within just the first 2.5 months of its launch.”Dr Manika Khanna, on the call for July to September 2026

What management guided

  • 10 centres planned in FY27 with 3 explained and sites for 5 of remaining 7 identified.
  • FY28-29 revenue growth around 25% aspiration versus 30% past pace; steady-state ROE around 22%.
  • Breakeven 5 cycles in 3-6 months, 25 cycles in 1-1.5 years, payback 1.5-2 years; Tier-2 ₹60 to ₹1 crore, metro ₹1.5 to ₹2 crore.
  • Receivables to reduce to about 20% this financial year on collection push.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 16 November 2026.

What to watch in Gaudium IVF and Women Health's next results?

When Gaudium IVF and Women Health reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Nagpur hub to move from ready-awaiting-approval to operational - licence clearance and first cycles the check.

Management raised each of these on the latest results call.

  • Nagpur hub to move from ready-awaiting-approval to operational - licence clearance and first cycles the check.
  • South Extension and Gurgaon scale toward early breakeven pace - cycle build and registration momentum the check.
  • Seasonally stronger H2 with Q4 peak expected - mature volumes plus new-hub contributions the check.
  • Receivables reduction toward year-end aim to progress - collection pace and aggregator conversion the check.

Which stock lists is Gaudium IVF and Women Health on?

Gaudium IVF and Women Health is on 2 of our India lists: Penny stocks and Healthcare & hospital stocks.

Is Gaudium IVF and Women Health profitable?

Gaudium IVF and Women Health Ltd earned ₹9.4 Cr of net profit in the Sep 2026 quarter, +0.3% on the same quarter a year earlier. Full-year FY26 profit was ₹24.0 Cr. Over 4 years profit has grown 27.8% a year on average. The Sep 2026 quarter's profit is 25.2% of that quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹9.4 Cr.

For the full year, FY26 profit was ₹24.0 Cr (+26.3% on the year before).

Why profit moved: revenue changed +17.9% on a year earlier and the margin moved −7.4 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −1.4% and revenue +27.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

How much revenue does Gaudium IVF and Women Health make, and is it growing?

Gaudium IVF and Women Health Ltd reported ₹37.4 Cr of revenue in the Sep 2026 quarter, +17.9% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 4 years it has grown 29.5% a year on average. The last full year, FY26, came in at ₹104 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹112 Cr.

FY26 revenue was ₹104 Cr, +46.5% on the year before.

Recent pace: the last four quarters grew +27.4% on average, against 29.5% a year over the longer run, so this year is growing slower than its own long-run rate.

How much of every ₹100 of sales does Gaudium IVF and Women Health keep?

Gaudium IVF and Women Health Ltd's operating margin was 36.0% in the Sep 2026 quarter, 7.4 percentage points lower than the same quarter a year ago. Across 5 years it has been between 36.5% and 45.5%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −7.4 percentage points on the year while gross margin changed +7.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Is Gaudium IVF and Women Health's profit turning into cash?

Over the last 3 years, 36% of Gaudium IVF and Women Health Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹7.0 Cr of operating cash against ₹24.0 Cr of profit. After ₹2.0 Cr of spending on assets, ₹5.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 36% of profit came in as cash: the cash cycle got 112 days longer between FY22 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 112 days longer. The next section looks at where the cash is stuck.

Where does Gaudium IVF and Women Health's cash go?

Gaudium IVF and Women Health Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 92 days in FY26, up from −20 days in FY22. It spent ₹14.0 Cr on assets over the last 3 years. Customers take 187 days to pay, and stock sits for 38 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹104 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹26.0 Cr is tied up in the business at any time.

FY26: customers took 187 days to pay and stock sat for 38 days, about 1.3 months of sales sitting as stock, for a full cycle of 92 days, longer than FY22's −20.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 38 days. Customers pay about 187 days after that. Suppliers are paid at 133 days. Together that makes the 92-day cycle.

Spending on assets: ₹14.0 Cr over the last 3 years, against ₹7.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹12.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

What is Gaudium IVF and Women Health's P/E ratio, and how does it compare with its own history?

Gaudium IVF and Women Health Ltd's P/E is 30.4×, near the low end of its own history: it has been lower only 11% of the time. Its usual P/E (the middle reading) is 37.5×, over 8 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹3.27.

30.4×P/E · lower than 89% of its last 8 months
n/mPEG · cannot be worked out, because 3-year earnings growth is not available

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Is the Gaudium IVF and Women Health business getting better or worse?

Gaudium IVF and Women Health Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Turning downROCE · latest (four quarters to Sep 2026) 25.2%, range 25.2% to 67.9%

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+46.5%+33.2%——
Profit+26.3%+19.7%——
EPS+7.7%+15.5%——
+17.9%Revenue growth (Sep 2026) · latest quarter against a year ago
+0.3%Profit growth (Sep 2026) · latest quarter against a year ago
29.5%Revenue, 4 years · yearly growth over the long run

How much does Gaudium IVF and Women Health earn on its capital?

Gaudium IVF and Women Health Ltd earned a ROCE of 30% in FY26. Its return on capital used (ROIC) is 3.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 23.1% net margin and 0.54× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 23.1% net margin × 0.54× asset turnover × 1.27× leverage (assets divided by equity) ≈ 15.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 15.2% − 12.0% = +3.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 15.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 23.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Does Gaudium IVF and Women Health have too much debt?

Gaudium IVF and Women Health Ltd has total debt of ₹23.0 Cr against shareholder equity of ₹163 Cr as of Sep 2026, so its debt is 0.14× its equity, which is very little. Year by year, that ratio went from 0.46 in FY25 to 0.16 in FY26.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

So the returns on this page come from the business, not from borrowed money.

What is the Gaudium IVF and Women Health shareholding pattern?

No group of Gaudium IVF and Women Health Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

How far is Gaudium IVF and Women Health from balance-sheet trouble?

For Gaudium IVF and Women Health Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Gaudium IVF and Women Health rank in its industry?

46.1 out of 100, rank 4 of 8 in Hospitals/Medical Services, with 63% of the evidence available.

Gaudium IVF and Women Health Ltd scores 46.1 out of 100 against the 8 companies it is compared with in Hospitals/Medical Services, ranking 4. There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.

The three scored parts add up to the total exactly: 9.5 + 22.8 + 13.8 = 46.1 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Gaudium IVF and Women Health compared with?

Gaudium IVF and Women Health ranks 4 of 8 Hospitals/Medical Services companies on the 4-Factor Sector Score, with 46.1 out of 100.

  1. 1Dr Agarwals Health Care LtdAGARWALEYE · turning · Evidence leans up · 60% evidence58.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.6/35 · Revenue 25.9% · Profit 42.1% · Operating margin change 0 points · 95% evidenceCapital efficiency 9.3/25 · ROCE 10.9% (year to Mar 2026) · Operating margin 26.9% · 76% evidenceValuation 8.5/20 · P/E 97.4× · PEG — · 15% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 11.5% · 1 year 12.1% · 25% evidence · 9 of 12 weeks aheadExact sum: 28.6 + 9.3 + 8.5 + 12.5 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Gujarat Kidney & Super Speciality LtdGKSL · breaking out · Evidence leans up · 63% evidence50.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.8/43.75 · Revenue 100% · Profit 68.2% · Operating margin change -12.8 points · 100% evidenceCapital efficiency 15.5/31.25 · ROCE 14.5% (year to Mar 2026) · Operating margin 26.8% · 100% evidenceValuation 11.2/25 · P/E 61.9× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 23.8 + 15.5 + 11.2 = 50.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  3. 3Park Medi World LtdPARKHOSPS · quiet · Too little evidence to rank firmly · 55% evidence48.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.0/43.75 · Revenue 22.9% · Profit 12.3% · Operating margin change -7 points · 95% evidenceCapital efficiency 17.3/31.25 · ROCE 19.5% (year to Mar 2026) · Operating margin 20% · 76% evidenceValuation 12.2/25 · P/E 40.1× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19 + 17.3 + 12.2 = 48.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  4. 4Gaudium IVF and Women Health Ltd this pageGAUDIUMIVF · quiet · Evidence leans down · 63% evidence46.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 9.5/43.75 · Revenue 22.9% · Profit 3.9% · Operating margin change -7.4 points · 100% evidenceCapital efficiency 22.8/31.25 · ROCE 29.5% (year to Mar 2026) · Operating margin 36% · 100% evidenceValuation 13.8/25 · P/E 30.4× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 9.5 + 22.8 + 13.8 = 46.1 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  5. 5Nephrocare Health Services LtdNEPHROPLUS · quiet · Evidence leans down · 64% evidence44.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.2/43.75 · Revenue 24.8% · Profit 100% · Operating margin change -5 points · 74% evidenceCapital efficiency 10.5/31.25 · ROCE 15.3% (year to Mar 2026) · Operating margin 20.8% · 100% evidenceValuation 14.7/25 · P/E 51.4× · PEG 1.22 · 65% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19.2 + 10.5 + 14.7 = 44.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  6. 6KRM Ayurveda LtdKRMAYURVED · Too little evidence to rank firmly · 38% evidence64.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 23.5/43.75 · Revenue — · Profit — · Operating margin change 12 points · 32% evidenceCapital efficiency 26.5/31.25 · ROCE 35.3% (year to Mar 2026) · Operating margin 37.2% · 95% evidenceValuation 14.4/25 · P/E 18.7× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 23.5 + 26.5 + 14.4 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  7. 7Unihealth Hospitals LtdUNIHEALTH · quiet · Too little evidence to rank firmly · 42% evidence53.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.7/35 · Revenue — · Profit — · Operating margin change -4 points · 15% evidenceCapital efficiency 16.7/25 · ROCE 24.5% (year to Mar 2026) · Operating margin 33.9% · 57% evidenceValuation 10.2/20 · P/E 32.9× · PEG — · 15% evidenceRelative strength 8.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -0.7% · Strength vs NIFTY 500 (same reading) 6.3% · 1 year 53.1% · 100% evidence · 5 of 12 weeks aheadExact sum: 17.7 + 16.7 + 10.2 + 8.9 = 53.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  8. 8Credent Connect N Care LtdCREDENT · Too little evidence to rank firmly · 38% evidence50.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.0/43.75 · Revenue — · Profit — · Operating margin change 0 points · 32% evidenceCapital efficiency 16.2/31.25 · ROCE 21.5% (quarter to Sep 2026) · Operating margin 13% · 95% evidenceValuation 13.3/25 · P/E 32.3× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 21 + 16.2 + 13.3 = 50.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals/Medical Services, all 8 compared on one page.

Which companies are close to Gaudium IVF and Women Health in size?

Gaudium IVF and Women Health is the 6th largest of 7 Hospitals/Medical Services companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Dr Agarwals Health Care, Park Medi World, Nephrocare Health Services, Gujarat Kidney & Super Speciality and Unihealth Hospitals. Just below it: KRM Ayurveda.

Hospitals/Medical Services companies close in size

  1. Dr Agarwals Health Care Ltd ₹17,545 crore
  2. Park Medi World Ltd ₹10,275 crore
  3. Nephrocare Health Services Ltd ₹6,595 crore
  4. Gujarat Kidney & Super Speciality Ltd ₹1,177 crore
  5. Unihealth Hospitals Ltd ₹844 crore
  6. Gaudium IVF and Women Health Ltd ₹725 crore
  7. KRM Ayurveda Ltd ₹468 crore

All 7 Hospitals/Medical Services companies, largest first

Companies close in size in other industries

  1. One Global Service Provider Ltd ₹729 crore · Diagnostics
  2. Hexagon Nutrition Ltd ₹727 crore · Food - Processing - Others
  3. Gaudium IVF and Women Health Ltd ₹725 crore
  4. Yogi Ltd ₹725 crore · Trading
  5. Gem Aromatics Ltd ₹724 crore · Chemicals - Organic

What else do people ask about Gaudium IVF and Women Health?

What is Gaudium IVF and Women Health's share price today?

Gaudium IVF and Women Health Ltd's share price is ₹99.57. The whole company is worth ₹726 Cr on the market.

In the last 52 weeks it traded between ₹92 to ₹158; today it is 11% of the way up from the low, 6.6% below its 200-day average (as of 20 November 2026).

What were Gaudium IVF and Women Health's latest quarterly results?

Gaudium IVF and Women Health Ltd reported revenue of ₹37.4 Cr and net profit of ₹9.4 Cr for the Sep 2026 quarter. Revenue rose 17.9% and profit rose 0.3% compared with a year earlier. Earnings per share were ₹1.29 (as of 20 November 2026).

What is Gaudium IVF and Women Health's market cap?

Gaudium IVF and Women Health Ltd's market capitalisation is ₹726 Cr at a share price of ₹99.57. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).

How is Gaudium IVF and Women Health performing?

Gaudium IVF and Women Health Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 17.9% and profit rose 0.3% compared with a year earlier. This describes what the data did, not a rating (as of 20 November 2026).

Is Gaudium IVF and Women Health in an uptrend?

Yes, the price has been rising for 31 weeks (stage 2 of 4), 6.6% below its 200-day average, and 11% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 20 November 2026).

Will Gaudium IVF and Women Health's share price go up?

This page does not forecast Gaudium IVF and Women Health Ltd's share price. What it shows instead: the share price is ₹99.57, and it has been rising for 31 weeks. Its P/E of 30.4× is higher than 11% of its own last 1 years (as of 20 November 2026).

Who owns Gaudium IVF and Women Health?

Promoters own 71.3% of Gaudium IVF and Women Health Ltd, foreign institutions 1.2%, domestic institutions 2.2% and the public 25.3% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026).

Where is Gaudium IVF and Women Health in its business cycle?

Gaudium IVF and Women Health Ltd's FY26 operating margin was 36.5%, against a 5-year range of 36.5% to 45.5%. The latest quarter was 36.0%, below the bottom of its own yearly range in the latest quarter, a low point in its cycle.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).

What could break the Gaudium IVF and Women Health story?

The main question: profits are rising, but only 36% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).

Is Gaudium IVF and Women Health a stock worth studying right now?

What the numbers show: Gaudium IVF and Women Health Ltd's results are improving, while its P/E is near the low end of its own history over 8 months, higher than only 11% of past readings. The main open question: whether the cash starts to follow the profit.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).

Is there a Gaudium IVF and Women Health share price forecast for 2026?

What management itself guided: FY27 revenue ₹130 crore reaffirmed with hub rollout on schedule and stronger H2 expected.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.